gel-e is a College Park, Md.-based clinical-stage medical device company that develops a broad range of hemostatic and wound treatment products. Its portfolio includes bandages for routine cuts and scrapes, foams and putties for traumatic and military injuries, and surgical gels and powders. The company holds an initial U.S. FDA regulatory clearance for management of bleeding wounds, including vascular access sites (Vascular gel-e®). gel-e intends to use the financing to expand that clearance to a broader hemostatic product line for treatment of external wounds and to establish cGMP manufacturing of its active ingredient. The company raised $3.1M in financing led by early-stage investment funds and life science investors. Prior to this financing, gel-e was funded by grants from the National Science Foundation (SBIR), the U.S. Army Research Lab, Maryland Industrial Partnerships, and TEDCO.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2017